---

---

tags : Trial    crawled date : 2021 - 10 - 18   

save search

---

STAG Industrial Maintains "B" GRESB Disclosure Rating
Published: 2021-10-18 (Crawled : 20:00) - prnewswire.com
STAG | $34.85 1.37% 380K |

Finance

| -19.26% | O: 0.42% H: 0.3% C: -0.55%
trial

---

Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
Published: 2021-10-18 (Crawled : 19:00) - biospace.com/
PHAT | $9.15 -3.48% 99K |

Health Technology

| -69.86% | O: 2.92% H: 0.0% C: -18.53%
positive results topline phase 3 trial

---

BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer
Published: 2021-10-18 (Crawled : 19:00) - biospace.com/
BTAI | $2.715 6.47% 180K |

Health Technology

| -90.59% | O: 0.15% H: 6.75% C: 3.39%
treatment phase 2 prostate cancer expansion endocrine cancer trial merge

---

Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
GERN | $3.79 1.61% 1.5M |

Health Technology

| 160.99% | O: 0.71% H: 3.52% C: 0.0%
risk phase 3 trial merge syndros enroll

---

Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
VRTX | News | $395.42 0.49% 290K |

Health Technology

| 117.29% | O: 0.4% H: 0.11% C: -0.93%
diabetes treatment stem cell phase 1 positive therapy trial

---

Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published: 2021-10-18 (Crawled : 17:00) - biospace.com/
RARE F | $43.45 0.16% 67K |

Health Technology

| -44.86% | O: -1.4% H: 0.27% C: -1.09%
disease treatment gene therapy therapy trial

---

Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Published: 2021-10-18 (Crawled : 13:00) - biospace.com/
MBRX | News | $4.5235 2.2K |

Health Technology

| 66.79% | O: 3.32% H: 0.0% C: -4.29%
treatment phase 1 trial phase 1b soft tissue phase 2b

---

DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021
Published: 2021-10-18 (Crawled : 13:00) - biospace.com/
DMAC | $2.49 1.5K |

Health Technology

| -38.59% | O: 2.23% H: 4.13% C: 1.7%
phase 2 trial kidney

---

Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System in Pulmonary Embolism Patients
Published: 2021-10-18 (Crawled : 12:15) - globenewswire.com
NARI S | $38.915 0.71% 99K |

Health Technology

| -53.97% | O: 1.75% H: 1.62% C: 0.19%
trial

---

LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
Published: 2021-10-18 (Crawled : 12:00) - prnewswire.com
LOGC | $2.07 -0.48% |

Health Technology

| -47.78% | O: 2.66% H: 1.04% C: -0.25%
genome editing results children trial trial results capsid engineering gene therapy

---

I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
Published: 2021-10-18 (Crawled : 12:00) - prnewswire.com
IMAB | $1.795 -0.28% 83K |

Health Technology

| -97.28% | O: -1.19% H: 4.34% C: 2.66%
phase 2 china therapy trial approval

---

CNH Industrial to announce 2021 Third Quarter financial results on November 4, 2021 and, in view of the announced spin-off (early 2022), an Iveco Group Investor Day on November 18, 2021
Published: 2021-10-18 (Crawled : 10:00) - globenewswire.com
CNHI | News | $12.34 -0.48% 770K |

Producer Manufacturing

| -26.34% | O: -1.1% H: 0.48% C: 0.24%
financial results results trial

---

Clinical Trial Supply And Logistics Market Size Worth $5.4 Billion By 2028: Grand View Research, Inc.
Published: 2021-10-18 (Crawled : 09:00) - prnewswire.com
CTLT | $55.965 0.3% 100K |

Health Technology

| -56.91% | O: -0.73% H: 1.64% C: 1.48%
research trial

---

COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial
Published: 2021-10-18 (Crawled : 07:00) - prnewswire.com
DVAX | $11.59 2.21% 490K |

Health Technology

| -33.41% | O: 2.23% H: 1.9% C: -1.55%
covid cpg 1018 vaccine phase 3 trial

---

Gainers vs Losers

79%

21%

Top 10 Gainers

AGBA | News | $1.22 205.0% 86M |

Finance

EGOX | $0.0606 68.33% 250M |

NVFY | $3.45 63.51% 20M |

Consumer Durables

CHRO | $1.66 35.51% 70K |

n/a

INDO | $5.43 33.09% 10M |

Energy Minerals

ZCMD | $1.86 28.28% 29M |

Commercial Services

PAPL | $2.07 26.22% 550K |

RWOD | $10.08 26.05% 5.6M |

n/a

AULT | $0.3022 24.82% 51M |

Manufacturing

HUSA 4 | $2.07 23.95% 2.1M |

Energy Minerals

---

Your saved searches

---